 |
|
COMMENTS AND OPINIONS
Studies of Monocular Trials of Glaucoma Medications: Conflicting Results Explained by Varying Methods—Reply
Omar Chaudhary, MD;
Ron A. Adelman, MD, MPH;
M. Bruce Shields, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Dr Leffler for his interest in our article.1 If we understand him correctly, however, he is referring to use of the monocular trial in establishing the efficacy of a topical glaucoma medication in 1 eye. While we agree that this is the main theoretical use of the monocular trial, our study was actually focusing on the other application, which is to predict the response to glaucoma therapy in one eye based on the response in the fellow eye. Of course, these 2 applications of the monocular trial are interrelated, and Dr Leffler's concern regarding subtraction of the contralateral IOP change is still pertinent to our study.
In our study, the response to a topical glaucoma medication in one eye was not predictive of the response in the fellow eye of patients with open-angle glaucoma, . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Predicting Response to Glaucoma Therapy in One Eye Based on Response in the Fellow Eye: The Monocular Trial
Omar Chaudhary, Ron A. Adelman, and M. Bruce Shields
Arch Ophthalmol. 2008;126(9):1216-1220.
ABSTRACT
| FULL TEXT
RELATED LETTER
Studies of Monocular Trials of Glaucoma Medications: Conflicting Results Explained by Varying Methods
Christopher T. Leffler
Arch Ophthalmol. 2009;127(5):707-708.
EXTRACT
| FULL TEXT
|
